Aquestive Therapeutics, Inc. 2025 Annual Report: Key Highlights for Investors

Overview

Aquestive Therapeutics, Inc. (“Aquestive” or “the Company”), trading on Nasdaq under the symbol AQST, has released its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The report details significant financial transactions, strategic developments, and notable risks, providing a comprehensive view of the company’s performance and prospects for shareholders.

Key Financial and Strategic Developments

• Public Offerings and Capital Raises:
  • In 2025, Aquestive completed an Underwritten Public Offering, raising gross proceeds of \$85 million. This follows a 2024 Underwritten Public Offering which raised \$77.5 million, including the partial exercise of underwriters’ options.
  • The company also maintains an At-The-Market (ATM) facility, providing flexibility to raise additional capital through the sale of common stock as needed.
• Securities and Capital Structure:
  • As of March 2, 2026, Aquestive had 122,045,049 shares of common stock outstanding.
  • The aggregate market value of common stock held by non-affiliates as of June 30, 2025, was approximately \$291.6 million.
• Debt and Notes:
  • The company redeemed its 12.5% Senior Secured Notes in November 2023 and now has outstanding 13.5% Senior Secured Notes, governed by the Indenture Agreement.
  • The 13.5% Notes are a significant part of the capital structure, and related Royalty Rights Agreements present ongoing liabilities.
• Royalty and Asset-Based Agreements:
  • Aquestive has entered into a Purchase and Sale Agreement with RTW Investments LP, involving a \$75 million purchase price. This includes transfer of rights to future royalties related to certain assets, which could affect the company’s recurring revenue streams.
  • Royalty Obligations and Rights Agreements remain a core part of the company’s financial commitments and are linked to the 13.5% Senior Secured Notes.
• Warrants and Equity Incentives:
  • The company has issued both “New Warrants” (2,750,000 shares) and “Existing Warrants” (5,000,000 shares) for the purchase of common stock, which could result in future dilution if exercised.
  • Multiple equity incentive programs, including Restricted Stock Units (RSUs) and Performance Shares, remain in place and could affect future share counts.

Regulatory and Market Information

• Aquestive remains listed on the Nasdaq Global Market (symbol: AQST), with all common stock registered under Section 12(b) of the Securities Exchange Act.
• The company is classified as a Non-Accelerated Filer and a Smaller Reporting Company, which impacts its disclosure and compliance obligations.
• Aquestive is not an Emerging Growth Company and is not a Well-Known Seasoned Issuer or a Shell Company.
• The company has not corrected any previous financial statement errors or restated financials in this filing.
• All required periodic and current reports, including Interactive Data Files, have been filed with the SEC for the relevant periods.

Risks and Forward-Looking Statements

Investors should be aware of several key risks highlighted in the report:

• Debt and Royalty Payment Risks: The company’s ability to refinance its 13.5% Senior Secured Notes and the impact of royalty obligations on liquidity were specifically noted as risk factors.
• Product Development and Regulatory Approvals: There is a risk that manufacturing capabilities may be insufficient to meet demand for product candidates, such as Anaphylm, should they receive FDA or other regulatory approval.
• Cybersecurity Threats: The company acknowledges risks related to cybersecurity and IT disruptions, which could impact operations and financial reporting.
• Economic and Geopolitical Uncertainty: The report references inflation, changing interest rates, pandemics, and geopolitical events (including the Ukraine and Israel wars) as potential sources of volatility.

The company’s forward-looking statements are subject to numerous risks, and management urges investors not to place undue reliance on these statements.

Important Shareholder Information

• Portions of the definitive proxy statement for the 2026 Annual Meeting of Shareholders will be incorporated by reference into Part III of the 10-K, to be filed within 120 days of fiscal year-end.
• No restatements or recoveries of executive compensation due to error corrections have occurred.
• The company’s significant capital raises, debt refinancings, and ongoing royalty obligations are all potentially price-sensitive and could impact the share value depending on future developments.

Conclusion

Aquestive Therapeutics, Inc. enters 2026 with a strengthened balance sheet due to substantial capital raises in 2024 and 2025, but carries significant debt and royalty obligations. The company is actively managing its capital structure, equity incentives, and regulatory risks. Shareholders should monitor developments relating to product approvals, debt refinancing, and ongoing compliance with SEC requirements, as these events may have material effects on stock valuation.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full Annual Report and consult with financial advisors before making investment decisions. Forward-looking statements are subject to risk and uncertainty; actual results may differ materially.

View Aquestive Therapeutics, Inc. Historical chart here